17-beta-hydroxysteroid dehydrogenase deficiency historical perspective
|
17-beta-hydroxysteroid dehydrogenase deficiency Microchapters |
|
Differentiating 17-beta-hydroxysteroid dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
17-beta-hydroxysteroid dehydrogenase deficiency historical perspective On the Web |
|
American Roentgen Ray Society Images of 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
FDA on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
CDC on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
17-beta-hydroxysteroid dehydrogenase deficiency historical perspective in the news |
|
Blogs on 17-beta-hydroxysteroid dehydrogenase deficiency historical perspective |
|
Directions to Hospitals Treating 17-beta-hydroxysteroid dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdulkerim Yassin, M.B.B.S[2]
Overview
17 beta hydroxysteroid dehydrogenase III deficiency was initially described in 1971 by Saez and his colleagues.
Historical Perspective
- 17 beta hydroxysteroid dehydrogenase III deficiency is initially described in 1971 by Saez and his colleagues.
- 17βHSD-3 enzyme deficiency, previously termed 17-ketosteroid reductase deficiency, is the most common testosterone biosynthesis defect of 46,XY disorder of sex development.
- It shows autosomal recessive inheritance.[1]
References
- ↑ Mains LM, Vakili B, Lacassie Y, Andersson S, Lindqvist A, Rock JA (2008). "17beta-hydroxysteroid dehydrogenase 3 deficiency in a male pseudohermaphrodite". Fertil Steril. 89 (1): 228.e13–7. doi:10.1016/j.fertnstert.2007.02.048. PMC 2259022. PMID 17509588.